How CHF Solutions is using health economics to expand product adoption

Two years after CHF Solutions (NSDQ:CHFS) acquired Baxter‘s (NYSE:BAX) Aquadex fluid filtration device for $5 million, the company’s executives are working to weave together the evidence they need to land reimbursement in the U.S. and expand patient access for its technology.

The Aquadex system is designed to filter water and salt from patients experiencing fluid overload due to heart failure. CHF Solutions, formerly known as Sunshine Heart, has plenty of clinical evidence to back up the device’s efficacy, according to VP of quality assurance & regulatory affairs Megan Brandt.

See Brandt address the latest trends in medtech policy at DeviceTalks Minnesota June 4-5

“Now I’m working to pull that economic story together, based off of clinical data that we have. While we may not have reimbursement, we can show that if you treat with our product, you can reduce hospital readmissions,” Brandt told MassDevice.com ahead of her appearance this summer at DeviceTalks Minnesota.

Get the full story at our sister site, MassDevice.com

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW